Inhibitor of nuclear factor jB kinase-a (IKKa) is required for maintaining skin homeostasis and preventing skin tumorigenesis. However, its signaling has not been extensively investigated. In the present study, we generated two mouse lines that expressed different levels of transgenic IKKa in the basal epidermis under the control of keratin-5 promoter and further evaluated their effects on the major pathways of inflammation, proliferation, and differentiation in the skin. Regardless of the transgenic IKKa levels, the mice develop normally. Because IKKa deletion in keratinocytes blocks terminal differentiation and induces epidermal hyperplasia and skin inflammation, we depleted the endogenous IKKa in these transgenic mice and found that the transgenic IKKa represses epidermal thickness and induces terminal differentiation in a dose-dependent manner. Also, transgenic IKKa was found to elevate expression of Max dimer protein 1 (Mad1) and ovo-like 1, c-Myc antagonists, but repress activities of epidermal growth factor receptor (EGFR), extracellular signal-regulated kinase (ERK), Jun-amino-terminal kinases, c-Jun, signal transducer and activator of transcription 3 (Stat3), and growth factor levels in a dose-dependent fashion in the skin. Moreover, EGFR reduction represses IKKa deletion-induced excessive ERK, Stat3 and c-Jun activities, and skin inflammation. These new findings indicate that elevated IKKa expression not only represses epidermal thickness and induces terminal differentiation, but also suppresses skin inflammation by an integrated loop. Thus, IKKa maintains skin homeostasis through a broad range of signaling pathways.
The inhibitor of nuclear factor (NF) kB (IkB), IkB kinase-a (IKKa), IKKb, and IKKg form the IKK complex that is essential for NF-kB activation.
1,2 NF-kB is a group of protein structuralrelated transcription factors, and it regulates the expression of many genes encoding proteins involved in many functions, including inflammation, immunity, apoptosis, cell migration, and cell cycle regulation. IKKa and IKKb are two highly conserved protein kinases that share many similar biochemical activities, and can form homodimers and heterodimers. 2 They can phosphorylate IkBs, which are inhibitors of NF-kB. This phosphorylation event induces the degradation of IkBs, resulting in NF-kB activation. IKKb has stronger activity for phosphorylating IkBs than IKKa does. Given the importance of the biological activities of IKK/NF-kB, deregulating their activities may elicit diseases. [3] [4] [5] Studies have demonstrated that either elevating NF-kB activity or reducing NF-kB activity can provoke skin inflammation in mice. 6, 7 Genetic studies have shown that IKKa regulates mouse embryonic skin development, but that IKKb and IKKg do not. [8] [9] [10] [11] [12] [13] Ikka À/À mice die soon after birth. [8] [9] [10] At birth, these mutant newborns have shining and thickened skin. Their epidermis is hyperplastic and lacks terminally differentiating keratinocytes.
The loss of water from the defective skin causes the death of the mutants. It has been shown that the overexpression of IKKa or kinase-inactive IKKa under the control of the keratin (K)-14 promoter or the K5 promoter is able to rescue the skin phenotype of Ikka À/À mice. 14, 15 Thus, IKKa is required for embryonic skin development, independent of its kinase activity.
Several laboratories have demonstrated that IKKa expression was downregulated, or that its localization was altered in human squamous cell carcinomas of the skin, lungs, and head and neck, [16] [17] [18] [19] [20] highlighting the importance of IKKa in human malignancy development. We showed that induced IKKa deletion in keratinocytes causes epidermal hyperplasia and spontaneous skin tumors. 15 We further identified that IKKa loss elevates an excessive autocrine loop of epidermal growth factor receptor (EGFR), Ras, extracellular signal-regulated kinase (ERK), EGFR ligands, and these ligands' activators in the epidermis of both Ikka À/À mice and Ikka F/F /K5.Cre mice, that reintroducing IKKa or inactivating EGFR induces keratinocytes to terminal differentiation, represses epidermal hyperplasia, and prevents skin tumors. Moreover, studies have demonstrated that IKKa upregulates c-Myc antagonists by transforming growth factor-b and Smad pathways in coordinately regulating keratinocyte differentiation and proliferation. 19, 20 Thus, IKKa acts as a sentry, monitoring the skin and, when necessary, halting keratinocyte hyperproliferation by multiple avenues.
It has been found that IKKa expression can be elevated in mice or cells in response to stresses, such as treatment with 12-O-tetradecanoylphorbol-13-acetate or ultraviolet light. [21] [22] [23] We also found that IKKa expression levels were higher in skin papillomas, a benign form of skin tumors, compared with normal skin in C57BL6 mice. 24 Approximately, only 3-5% of the papillomas progress to malignant carcinomas, but the rest eventually regress in C57BL6 mice. 24 We found that C57BL6 Ikka þ /À mice developed twice as many papillomas as C57BL6 Ikka þ / þ mice. The levels of 12-O-tetradecanoylphorbol-13-acetate-induced IKKa were obviously lower in Ikka þ /À skin and papillomas than in Ikka þ / þ skin and papillomas, indicating that IKKa levels are important for preventing skin tumor development.
IKKa is one of the subunits in the IKK complex. Recently, Page et al. 25 showed that the overexpression of IKKb in the basal epidermis under the control of the K5 promoter induces constitutive NF-kB activity, and a chronic inflammation disease in the skin of K5-IKKb transgenic mice. As mentioned above, elevated NF-kB activity, indeed, participates in the development of skin inflammation. 6, 7 Inflammation is important for the development of various skin diseases and skin tumors. However, whether and how IKKa affects skin inflammation development has not been extensively investigated.
In the current study, we evaluated the effect of different levels of transgenic K5.IKKa on skin development, homeostasis, and inflammation. Unlike IKKb in the skin, we found that the overexpression of IKKa did not cause skin inflammation and diseases, but it repressed inflammation and cellproliferating pathways in mice. These findings suggest that IKKa may be a potential target for preventing skin diseases.
Results
Mice overexpressing different levels of the IKKa transgene in basal epidermal keratinocytes develop normally. To determine the effect of IKKa doses on skin development, we generated two transgenic mouse lines, Tg-K5.IKKa-7 (Tg-7) and Tg-K5.IKKa-4 (Tg-4), with an FVB background, in which human IKKa cDNA tagged with hemagglutinin-A (HA) was driven by the K5 promoter ( Figure 1a) . We have not observed any pathological changes in the skin or any illnesses in these mouse lines, compared with wildtype (WT) mice over the past 6 years. Southern blotting hybridized with an N-terminal IKKa cDNA probe showed that Tg-4 mice had more copies of the IKKa transgene than Tg-7 mice (Figure 1b) . Western blotting showed a much higher transgenic IKKa level in the skin and epidermis of Tg-4 mice than in those of Tg-7 mice, and these transgenes were specifically expressed in the epidermis, but not in other organs (Figures 1c and d) . The transgenic Tg-4-IKKa level was higher than the endogenous IKKa level, whereas the transgenic Tg-7-IKKa level was slightly lower than the endogenous IKKa level in mice. A histological examination revealed no significant differences in the thickness of the epidermis of WT, Tg-7, and Tg-4 newborns (Figure 1e ). Together, these results suggest that different levels of overexpressed IKKa in the basal epidermis do not interrupt embryonic development and skin formation in mice.
We further examined the dorsal skin morphology of WT, Tg-7, and Tg-4 mice at 3 months of age, using hematoxylin and eosin staining and found no differences among the three specimens (Figure 2a; Supplementary Figure 1) . Gel-shift and IKK kinase assays revealed no elevated NF-kB DNA-binding activity or IKK kinase activity in the skins and epidermis of Tg-7 and Tg-4 mice, compared to WT mice (Figures 2b and c) . These results suggest that overexpressed IKKa in the basal epidermis has no significant effect on IKK and NF-kB activity in the skin. 26 Histological examinations revealed that Tg-4-IKKa completely rescued the epidermal phenotypes of Ikka À/À mice, but that some regions of the epidermis of Tg-7/Ikka À/À mice retained hyperplasia, similar to the epidermis in Ikka À/À mice, although most of the Tg-7/Ikka À/À epidermal regions were rescued (Figure 3b ). Immunofluorescence staining confirmed that the HA-tagged Tg-4-IKKa level was higher than HA-tagged Tg-7-IKKa in the nuclei of the epidermal cells in mice (Figure 3c ). We did not find HA staining signals in Ikka À/À skin (data not shown). These results indicate that the level of transgenic IKKa is important for rescuing the skin phenotype of Ikka À/À mice. No milk was found in the stomachs of Tg-4/Ikka À/À and Tg-7/Ikka À/À newborns, and these mice died at birth, likely due to a defect in taking milk, as previously reported. 14 Next, we evaluated the terminal differentiation marker filaggrin using western blotting, and found that transgenic Tg-7-IKKa and Tg-4-IKKa elevated filaggrin expression in the mouse skin (Figure 3d ). The level of filaggrin was slightly higher in the skin of Tg-4 mice than in the skin of Tg-7 mice. Furthermore, both transgenic Tg-7-IKKa and Tg-4-IKKa were able to induce terminal differentiation in the skin of Ikka À/À mice, and the filaggrin levels in Tg-4-IKKa skin were slightly higher than in Tg-7-IKKa skin (Figure 3d ). Thus, a higher level of transgenic IKKa has stronger activity in rescuing the Ikka À/À skin phenotype and inducing terminal differentiation in mice when the endogenous IKKa is absent. We also noticed that the filaggrin level was higher in Tg-7 skin than in WT skin (Figure 3d ). Transgenic HA-IKKa expression is under the control of a bovine K5 promoter. Although two HA-IKKa transgenes can rescue the skin phenotypes of Ikka À/À mice, the bovine K5 promoter and endogenous Ikka promoter may not be expressed at the same time, which may cause the inconsistence.
To further characterize the differentiation status induced by Tg-7-IKKa and Tg-4-IKKa in the epidermis of Tg-7/Ikka À/À and Tg-4/Ikka À/À newborn mice, compared with Ikka À/À newborn mice, we performed hematoxylin and eosin and immunohistochemical staining of mitotic marker p-H3, 27 basal epidermal cell marker K14, intermediate differentiation marker K10, and terminal differentiation marker loricrin. The entire thick Ikka À/À epidermis had substantially more p-H3-and K14-stained cells than other genotype samples, and the Ikka À/À suprabasal epidermis expressed K10, but did not express loricrin ( Figure 4 ). Transgenic Tg-7-IKKa and Tg-4-IKKa dramatically repressed epidermal thickness and p-H3-stained cells in the epidermis of Ikka À/À mice; however, the epidermis of Tg-7/ Ikka À/À mice had more p-H3-positive cells and was thicker than that of Tg-4/Ikka À/À mice. Loricrin staining intensity in the epidermis of Tg-4/Ikka À/À mice was higher than in the epidermis of Tg-7/Ikka À/À mice. K10 staining intensity in the epidermis of Tg-4/Ikka À/À and Tg-7/Ikka À/À mice was similar, although K10 staining appeared to be slightly weaker in the epidermis of Tg-7/Ikka À/À mice than in the epidermis of Tg-4/ Ikka À/À mice ( Figure 4 ). WT mice were used as controls. These results suggest that transgenic IKKa levels are important for regulating epidermal keratinocyte proliferation and terminal differentiation in mice by a dose-dependent manner.
To further determine whether transgenic IKKa also represses epidermal hyperplasia in postnatal mice lacking IKKa in the epidermis, we introduced Tg-4-IKKa and Tg-7-IKKa into Ikka F/F /K5.Cre mice. 15 Previously, we showed that IKKa deletion in the epidermis causes keratinocyte proliferation and reduces cell differentiation through the EGFR/Ras/ ERK pathway. 15 We found that both Tg-4-IKKa and Tg-7-IKKa rescued the epidermal hyperplasia in Tg-4/Ikka F/F /K5.Cre and Tg-7/Ikka Transgenic IKKa-mediated molecular alterations involved in keratinocyte proliferation and differentiation are IKKa dose-dependent. Previously, we detected elevated autocrine activity of EGFR and growth factors through a transcriptional regulation mechanism in IKKa-deficient keratinocytes. 15 Also, it has been reported that IKKa regulates the expression of Max dimer protein 1 (Mad1) and ovo-like 1 (Ovol1), which are differentiation inducers and c-Myc antagonists. 20 Thus, we evaluated whether different levels of transgenic IKKa have different effects on EGFR activity, and on Mad1 and Ovol1 expression levels. Western blotting showed that Tg-7-IKKa and Tg-4-IKKa not only repressed EGFR activity in the skins of mice with a WT background, but also strongly repressed IKKa loss-induced EGFR activity in the skin of Ikka À/À mice in an IKKa dose-dependent manner (Figure 6a ). On the other hand, IKKa induced Mad1 and Ovol1 expression in a dosedependent fashion (Figures 6a and b) .
To further verify the effect of IKKa on Mad1 expression in keratinocytes, we re-expressed a series of IKKa doses in keratinocytes lacking the endogenous IKKa isolated from Ikka F/F /K5.Cre mice 15 and found that Mad1 expression was induced by IKKa in a dose-dependent fashion. Filaggrin levels were used as controls for IKKa introduction, 28 because IKKa induces terminal differentiation in keratinocytes (Figure 6c ). We have reported that IKKa loss upregulates the expression of heparin-binding epidermal growth factor (HB-EGF), an EGFR ligand, which forms an autocrine loop with EGFR, Ras, and ERK. 15 Western blotting also showed that re-expression of IKKa repressed levels of HB-EGF, but induced expression of filaggrin in an IKKa dose-dependent manner (Figure 6c ). Together, these results indicate that IKKa can regulate keratinocyte proliferation and differentiation through the EGFR and Mad1/Ovol1 pathways.
Transgenic IKKa and reduced EGFR repress IKKa loss-mediated mitogen-activated protein kinase, activator protein 1 (AP-1), and signal transducer and activator of transcription 3 (Stat3) activities and skin inflammation. To explore those important pathways involved in inflammation, proliferation, and migration in IKKa-deficient skin, we examined ERK, Jun-amino-terminal kinase (JNK) 1/2, p38, c-Jun, and Stat3 activity in the skin of À/À and Tg-7/Ikka À/À skins, compared with Ikka À/À skin. We did not observe a significant effect of IKKa levels on p38 activity in the skin (Figure 7a ).
Because inactivating EGFR prevented skin tumor development in Ikka F/F /K15CrePR1 mice, 15 we further tested the effect of EGFR on the ERK, Stat3, and activator protein 1 (Ap-1) pathways in Ikka F/F /K5.Cre mice, and we found that reducing EGFR repressed ERK, c-Jun, and Stat3 activities, epidermal hyperplasia, and infiltrating cells in the skin stroma (as an inflammation indicator; Figures 7b and c) . Because IKKa inhibits EGFR activity in the epidermis, 15 we further determined whether EGFR reduction affects Stat3 activity and skin inflammation in Ikka Figure 2) . Further analysis for cytokine expression consistently showed elevated interleukin-1 (IL-1), IL-6, and tumor necrosis factor alpha (TNFa) in Ikka (Figures 8b and c) . Thus, IKKa deletion induces chronic skin inflammation and Stat3 activity; reduced EGFR or elevated IKKa can downregulate Stat3 activity and abolish skin inflammation. In Figure 8d , we summarized those pathways that IKKa utilizes in regulating keratinocyte differentiation, proliferation, and skin inflammation while maintaining skin homeostasis.
Furthermore, we evaluated the protein levels of IKKa, IKKb, IKKg, RelA (p65), p-p65, NF-kB2 p100/p52, IkBa, p-IkBa, and RelB in the skin of WT, Tg-7, Tg-4, Ikka À/À , Tg-7/Ikka À/À
, and Tg-4/Ikka À/À mice. No significant differences in the levels of most of these tested molecules were detected in the skin specimens (Supplementary Figure 3) . Although p52 levels in Tg-7 and Tg-4 skin were elevated compared with WT skin, there were no increased inflammation and no morphological changes in the skin of these transgenic mice (Figure 2a ; Supplementary Figure 1) . Furthermore, p52 levels were also elevated in Tg-7/À/À and Tg-4/À/À, compared with Ikka Figure 3) . These results suggest that there was not a close relationship between p52 levels and skin phenotypes in these mice. Thus, the elevated p52 levels may not be a major player in IKKa-mediated activity during embryonic skin development.
Discussion
In this study, we found that the overexpression of IKKa did not interrupt skin development, but rather induced an inhibitory effect on the epidermis thickness and skin inflammation in mice in an IKKa dose-dependent manner through a broad range of pathways. This finding provides insight into the mechanism by which IKKa prevents skin diseases.
Many studies have shown that the overexpression of IKKa elevates IKK and NF-kB activity in cell lines. Overexpressed NF-kB p65 or p50, or deletion of IkBa in the basal epidermis has been shown to cause neonatal lethality or skin inflammation in mice. 6, 7, 31 Because depleting TNFR can rescue skin phenotypes of K5-mIkBa transgenic mice, the different cytokine profiles of NF-kB activity in the epidermis and the dermis have been thought to be a cause for the skin phenotypes in mice overexpressing mIkBa in the epidermis. 32 However, depleting TNFR does not rescue the skin phenotypes in mice with IKKa deletion in the epidermis. 15 Overexpressed IKKb elevates IKK/NF-kB activity and causes an inflammatory skin disease in K5-IKKb mice. 25 Although IKKa and IKKb are highly conserved protein kinases, our results here clearly showed that elevated IKKa expression in the epidermis did not provoke IKK/NF-kB activity and skin inflammation, and did not affect skin development in mice. Thus, overexpressed IKKa and IKKb/NF-kB may have different physiological roles in the skin. Also, it is possible that some cell lines and tissues may respond differently to the IKKa-led signaling pathways.
In this study, we found that the Tg-4/Ikka À/À newborns had a normal appearance, but that the Tg-7/Ikka À/À newborns retained some phenotypes from Ikka À/À mice, indicating that Tg-4-IKKa, but not Tg-7-IKKa, completely rescued phenotypes of Ikka À/À mice, and IKKa dose is important for mouse embryonic development. In addition, Tg-4-IKKa showed stronger activity in inhibiting ERK and EGFR activity, and epidermal mitotic activities in the epidermis of Ikka À/À mice than Tg-7-IKKa. Previously, we reported that EGFR and ERK activities, and HB-EGF levels are involved in IKKa-mediated keratinocyte differentiation and proliferation regulation. 15 Here, we detected an IKKa dose-dependent inhibitory effect on IKKa loss-induced EGFR and ERK activities, and HB-EGF levels in the skin and keratinocytes. Thus, IKKa doses are also important for suppressing excessive mitosis of keratinocytes. On the other hand, Descargues et al. 20 and Marinari et al. 19 have shown that IKKa regulates the expression of Mad1 and Ovol1, c-Myc antagonists, through transforming growth factor-b/smad, in keratinocytes, skin, and skin tumors in human and mice, and that Mad1 and Ovol1 are required to induce keratinocyte differentiation and inhibit keratinocyte proliferation. In the present study, we found that transgenic IKKa substantially induced the expression of Mad1 and Ovol1 in a dose-dependent manner, and that the expression levels of Mad1 and Ovol1 were well correlated with IKKa levels and differentiation levels in the skin and keratinocytes. Together, these results suggest that IKKa regulates keratinocyte differentiation and proliferation through the two antagonizing pathways of EGFR-ligands/ERK/EGFR and Mad1/Ovol1 in maintaining skin homeostasis in a dose-dependent manner. Interestingly, although Tg-4 mice expressed much higher levels of transgenic IKKa than Tg-7 mice, the level of filaggrin in Tg-4 mice was slightly higher than that in Tg-7 mice. However, when endogenous IKKa was absent, the epidermis of Tg-4/Ikka À/À mice expressed much higher levels of filaggrin 15,20 kIDF, keratinocyte-inducible differentiation factor(s). 28 Transcriptional regulation was previously described. 15 Arrow indicates upregulation. Line with vertical line at the end indicates downregulation and loricrin than Tg-7/Ikka À/À mice. The expression of the intermediate differentiation marker K10 did not differ significantly between Tg-7/Ikka À/À and Tg-4/Ikka À/À mice. It appears that IKKa is important for inducing terminal differentiation; however, there is a saturated state of overexpressed IKKa in the induction of terminal differentiation. Because our data showed that an increased IKKa dose had a biologically significant function in maintaining epidermal homeostasis, a higher level of IKKa may be better at antagonizing excessive mitotic activity in the skin.
We also noticed that although the transgenic IKKa generally affects these tested molecules in a dose-dependent manner, it appears that the impact of IKKa doses on the individual target has differences, compared with the transgenic IKKa levels between Tg-7 and Tg-4 mice. On the other hand, IKKa doses well induce or inhibit its targets in cultured keratinocytes in a dose-dependent fashion (Figure 6c) . Together, these results suggest that the altered levels of IKKa's targets are not only caused by IKKa doses, but also affected by IKKa-mediated multi-changes in vivo (crosstalking). Thus, the impact of IKKa on these tested pathways may not equal in animals.
c-Jun is one of the AP-1 proteins, which are prototypic oncogenes, and it regulates keratinocyte proliferation and differentiation, skin inflammation, and skin cancer. 33, 34 The EGFR/HB-EGF pathway is important for the AP-1 pathway in maintaining skin homeostasis. Jun/AP-1 proteins also regulate the expression of cytokines, such as IL-6 and TNFa. JNKs can activate Jun proteins. 34 In the present study, we found elevated JNKs and c-Jun activities in the skin of Ikka À/À mice, and we found that the transgenic IKKa or reduced EGFR repressed these activities in an IKKa dosedependent manner. Thus, the enhanced JNK and c-Jun activities may contribute to the epidermal hyperplasia, skin inflammation, and tumorigenesis in IKKa-deficient mice.
Many cytokines and growth factors, including IL-6 and EGF, can activate Stat3. 35, 36 Stat3 induces the expression of a large array of inflammatory mediators. In the skin, excessive Stat3 activity has a crucial role in inducing and maintaining a pro-carcinogenic inflammatory microenvironment and promoting skin carcinogenesis. 36 Here, we showed that IKKa loss elevated Stat3 activity and that transgenic IKKa repressed Stat3 activity in the skin in a dose-dependent fashion. It has been shown that deleting Stat3 in keratinocytes reduces chemical carcinogen and ultraviolet B-induced skin carcinogenesis, and that overexpressed Stat3 in the epidermis promotes skin carcinogenesis. [36] [37] [38] Conversely, deleting IKKa in keratinocytes causes spontaneous skin tumors, 15 reducing IKKa expression promotes chemical carcinogen and UVB-induced skin carcinogenesis, 24, 27 and overexpressing IKKa in the epidermis inhibits the development of malignant skin tumors and metastases induced by chemical carcinogens. 16 It appears that Stat3 and IKKa have converse roles in skin carcinogenesis, although IKKa seems to have a more specific effect on embryonic skin development and keratinocyte differentiation than Stat3 does. [8] [9] [10] 28, 39 Furthermore, we showed that reducing EGFR repressed Stat3 activity, epidermis thickness, and inflammation in IKKa-deficient skin. Previously, we showed that IKKa suppresses EGFR activity in keratinocytes. 15 and K5-IKKa transgenic mice were crossed to obtain K5-IKKa/Ikka À/À mice, which were identified by genotyping. 8 Gel shift assay. Electrophoretic mobility shift assays of NF-kB DNA-binding activity were performed using a kit (E3300; Promega, Madison, WI, USA). The NF-1 probe was purchased from Santa Cruz Biotechnology Inc. (sc-2553; Santa Cruz, CA, USA). A reaction containing 7.5 ml of 2 Â electrophoretic mobility shift assay buffer, 1.5 mg of poly dI-dC, 10 mg of protein lysates, 5 Â 10 3 cpm NF-kB probe, and up to 15 ml of water was incubated at room temperature for 30 min. The protein from HEK 293 cells (5 mg) and the protein from skin samples (30 mg) for each reaction was tested. A 5% non-denatured polyacrylamide gel was pre-run in 0.5 Â tris borate EDTA for 1.5 h at 100 V, and the reactions were subjected into the gel. The gel was dried and exposed to film.
Western blot analysis, immunohistochemical staining, and immunoinflorescence staining. Cell lysates (40 mg) or protein extracts from tissues (50 mg) were applied to an acrylamide gel, and the levels of protein expression were measured using western blotting with specific antibodies, as previously described. 8, 15 The Immunofluorescent staining of HA was performed as previously described. 28 IKK kinase assay. For the immunocomplex IKK assay, glutathione S-transferase-IkBa (amino acids 1À54) was used as a kinase substrate. 1 An anti-IKKg antibody was used to immunoprecipitate the IKK complex from 100 mg of protein lysates.
Southern blot assay. Genomic DNA was isolated from normal skin with an extraction kit (Promega). Southern blotting was performed according to the manufacturer's instructions (Bio-Rad, Hercules, CA, USA). In brief, DNA (10 mg) was digested overnight with BamHI, applied to a 0.9% agarose gel, transferred to Zeta-Probe GT blotting membranes (162-0197, Bio-Rad), and fixed by ultraviolet light. The DNA-blotting membranes were hybridized with an N-terminal IKKa cDNA (nucleotides 1À575) probe.
Keratinocyte culture. Mouse primary keratinocytes were isolated and cultured, as previously described. 28 In brief, skin specimens isolated from newborn mice or E19 embryos were treated with 0.25% trypsin (15050-065; Invitrogen, Rockville, MD, USA) for 8 to 10 h at 4 1C; the epidermis was separated from the dermis. The isolated keratinocytes were plated onto 60-cm cell dishes containing a keratinocyte serum-free medium (10785; GIBCO, Rockville, MD, USA). The reintroduction of different IKKa doses in cultured keratinocytes was performed, as previously described. 28 Reverse transcriptase-PCR. Total RNA was isolated from the epidermis or keratinocytes using TRI Reagent (Molecular Research Center). 24 cDNA was synthesized by a RETROscript kit (Ambion, Inc., Austin, TX, USA). PCR primers used included TNFa (5 0 -CACCACGCTCTTCTGTCTACTGAAC-3 0 and 5 0 -TGAGAT AGCAAATCGGCTGACG-3 0 ), IL-6 (5 0 -TCTGGGAAATCGTGGAAATGAG-3 0 and 5 0 -TCTCTGAAGGACTCTGGCTTTGTC-3 0 ), IL-1 (5 0 -CCAGGATGAGGACATGA GCACC-3 0 and 5 0 -TTCTCTGCAGACTCAAACTCCAC-3 0 ), and glyceraldehyde-3-phosphate dehydrogenase.
